Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2025-07-07 Declaration of Voting R…
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Comunicazione dell'ammontare complessivo dei diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official communication from Diasorin S.p.A. dated July 7, 2025, titled 'Comunicazione dell'ammontare complessivo dei diritti di voto ai sensi dell'art. 85-bis, comma 4-bis, del Regolamento Consob n. 11971/1999'. This explicitly deals with the total number of voting rights and changes therein, which falls under the category of shareholder voting rights announcements or related regulatory disclosures concerning voting structure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for a formal communication detailing the total voting rights capital structure, especially when triggered by specific regulatory articles (Consob Regulation). It is not an AGM presentation (AGM-R), a full annual report (10-K), or a general earnings release (ER).
2025-07-07 Italian
Diasorin S.p.A. - Allegato 3F
Transaction in Own Shares Classification · 99% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Disclosure Form for Transactions in the Issuer's Securities), which details transactions involving the company's own shares (treasury shares) being transferred to employees as part of equity award plans. This type of filing, which reports transactions in the company's own shares by the issuer itself, directly corresponds to the definition of 'Transaction in Own Shares' (POS). Key indicators are: 1. The structure and content match regulatory forms for insider/issuer transactions. 2. The notes explicitly state: "Trattasi di cessione a titolo gratuito di azioni proprie in favore di dipendenti..." (Transfer for free of treasury shares in favour of employees...). 3. Section 2 details the transactions, and Section 3 relates to the program for the purchase and sale of treasury shares. 4. This is distinct from Director's Dealing (DIRS), as the transaction is by the Issuer (Diasorin S.p.A.) itself, not an executive/director. 5. It is not a general regulatory filing (RNS) because it fits the specific category POS.
2025-07-01 Italian
Pubbicazione del verbale dell'Assemblea degli Azionisti del 28 aprile 2025
AGM Information Classification · 99% confidence The document is a short regulatory announcement (4124 characters) from Diasorin dated May 12, 2025. The subject ('Oggetto') explicitly states: 'Pubbicazione del verbale dell'Assemblea degli Azionisti del 28 aprile 2025' (Publication of the minutes of the Shareholders' Meeting of April 28, 2025). The text confirms that the minutes ('verbale') have been made available to the public on the company website and storage mechanism. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report (in this case, the meeting minutes) has been published, points towards a Report Publication Announcement (RPA), rather than the minutes document itself (which would likely be classified under AGM-R if it were the full minutes, but this is just the notice of publication).
2025-05-12 Italian
Verbale Assemblea Ordinaria degli Azionisti 28 aprile 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document text contains detailed tables showing shareholder voting results ('Voti per i quali il RD dispone di istruzioni per l'OdG in votazione', 'Favorevole', 'Contrario', 'Astenuto') related to specific agenda items, such as 'Punto 1.1: Bilancio di esercizio al 31 dicembre 2024 e destinazione dell'utile di esercizio: Approvazione del Bilancio di esercizio...'. Furthermore, it lists numerous 'Azionisti Rilevanti' (Major Shareholders) and a detailed breakdown of votes by individual shareholder ('Anagrafica'). This structure is characteristic of the official minutes or results declaration following a General Meeting of Shareholders. Since the document explicitly details the voting outcomes for resolutions presented at a meeting, the most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting.
2025-05-12 English
Diasorin Q1 2025 Results Presentation
Earnings Release Classification · 95% confidence The document explicitly states "Q1 2025 RESULTS" at the beginning and presents detailed financial highlights (Revenues, Adjusted EBITDA, Net Profit) and operational updates for the first quarter of 2025. This structure—a presentation format summarizing recent quarterly performance with financial tables and management commentary—is characteristic of an Earnings Release (ER) or an Investor Presentation (IP). Since it contains detailed financial tables and management outlook, it leans towards a comprehensive presentation rather than just a brief press release. However, the format strongly resembles an Investor Presentation (IP) used to walk through quarterly results, often accompanying or preceding a formal Earnings Release. Given the detailed slides, financial metrics, product development updates, and outlook, 'Investor Presentation' (IP) is the most fitting classification, as it is a structured document designed for investor consumption detailing performance and strategy. It is not a 10-K (Annual Report) because it is quarterly. It is not a CT (Call Transcript) because it is a prepared document, not a transcript. It is more detailed than a typical ER (Earnings Release) which is usually a short press release. Therefore, IP is selected. Q1 2025
2025-05-06 English
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance
Earnings Release Classification · 98% confidence The document is a press release from Diasorin S.p.A. dated May 6, 2025, announcing the 'Q1 Results' with key financial metrics like Revenues (€ 313 million, +8%) and Adjusted EBITDA margin (34%). It includes detailed tables of Q1 2024 vs Q1 2025 results, business highlights, and confirms the FY 2025 guidance. This structure—a summary of period results, key performance indicators, and management commentary—is characteristic of an Earnings Release (ER). Although it contains financial data, it is the initial announcement of the results, not the comprehensive, formal quarterly report (which would be an 'IR'). The document also mentions the approval of the enhanced voting rights mechanism, but the primary focus and structure are financial results reporting. Q1 2025
2025-05-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.